Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports. Check Now!

CRC

Feb 06, 2023

Will Merck’s P2X3 Receptor Antagonist for Chronic Refractory Cough Treatment Be Able to Turn FDA’s Nay Into Yea?

Feb 01, 2021

Chronic Refractory Cough Market and the Monopoly of the Over-The-Counter Drugs

Aug 10, 2020

Merck; Bayer; Shionogi set to showcase their candidates indicated for Chronic RefractoryCough in the ATS Virtual Conference

Newsletter/Whitepaper